FY26 Financial Results and Operational Update Presentation
| Stock | ARTRYA Ltd (AYA.ASX) |
|---|---|
| Release Time | 1 Sep 2026, 8:33 a.m. |
| Price Sensitive | Yes |
Artrya Ltd FY26 Financial Results and Operational Update
- FY26 revenue base established with minimum contracted revenue secured across three foundation customers
- $74.0m cash as at 30 June 2026
- Salix® Coronary Plaque launched commercially in the U.S.
- FDA clearance for Salix® Coronary Flow targeted by end of 2026
- Strong balance sheet supporting U.S. infrastructure and growing sales pipeline
Artrya Ltd has released its FY26 financial results and operational update, showcasing key achievements and financial performance. The company successfully established a commercial revenue base, secured minimum contracted revenue across three foundation customers, and reported a strong cash position of $74.0 million as at 30 June 2026. Salix® Coronary Plaque has been launched commercially in the U.S., with FDA clearance for Salix® Coronary Flow targeted by the end of 2026. The company's robust balance sheet supports ongoing U.S. infrastructure and a growing sales pipeline.
FY26 revenue base established with minimum contracted revenue secured across three foundation customers
FDA clearance for Salix® Coronary Flow targeted by end of 2026, supporting ongoing U.S. infrastructure and growing sales pipeline.